secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-110945
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio PAO Erin Butler to depart; Bob Lally named as successor
------------------------------------------------------------------

- Mutual separation of Erin Butler, SVP Finance & Administration and Principal Accounting Officer, effective March 20, 2026.
- Bob Lally, SVP Finance & Operations, appointed as Principal Accounting Officer effective March 20, 2026.
- Butler to receive severance per existing Severance Rights Agreement dated October 21, 2024.
- Lally previously served at Ikena Oncology (SVP Finance & Operations) and Prevail Therapeutics (VP Finance, COO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526110945/0001193125-26-110945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526110945/d56716d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-110945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer